Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement to acquire the Wellness Portfolio of Group Pharmaceuticals Limited. The acquisition, structured as a slump sale on a going-concern basis, carries a total consideration cap of ₹46.7 crore.

The transaction is designed to strengthen Jagsonpal's pharmaceutical portfolio and expand its presence in therapeutic segments, particularly women's healthcare. The deal was announced on September 23, 2026, with completion expected on or before November 1, 2026, subject to customary closing conditions.

Deal Structure and Consideration

The financial terms of the acquisition involve an initial payment followed by a performance-linked earn-out. This structure aligns the final payout with the future commercial performance of the acquired assets.

Strategic Rationale

Jagsonpal stated that the acquisition aligns with its strategic objective of enhancing market reach and integrating established products into its existing commercial platform. The company aims to leverage its distribution network to create operating synergies.

Manish Gupta, Managing Director of Jagsonpal, noted that the move strengthens the company's presence in complementary therapeutic segments while maintaining an asset-light growth approach. Amrut Medhekar, Chief Operating Officer, emphasized the commitment to seamless integration and cross-selling opportunities across the expanded portfolio.

What the Numbers Show

A comparison of the transaction value against the target's historical revenue reveals a significant valuation premium relative to current earnings. The Wellness Portfolio generated a turnover of ₹24.6 crore in FY26. With an initial consideration of ₹23.7 crore, Jagsonpal is paying nearly one times the annual revenue upfront. The total potential outlay of ₹46.7 crore represents approximately 1.9 times the FY26 turnover. This structure suggests Jagsonpal is pricing the deal based on projected growth in the women's health segment rather than historical revenue alone, betting that the portfolio will scale significantly by FY28 to justify the earn-out component.

Transaction Details

• Acquirer: Jagsonpal Pharmaceuticals Limited
• Seller: Group Pharmaceuticals Limited
• Asset Acquired: Wellness Portfolio (products, assets, contracts, employees)
• Method: Slump sale on going-concern basis
• Regulatory Status: No governmental or regulatory approvals required
• Related Party Status: Not a related party transaction; no promoter interest in the seller
• Legal Advisors: Think Law Advisors (for Jagsonpal); Tatva Legal (for Group Pharma)

Jagsonpal Pharmaceuticals has released the voting results for its 47th Annual General Meeting (AGM) held on September 18, 2026. The company confirmed that all five resolutions proposed during the meeting were passed with substantial shareholder support.

The AGM was conducted via Video Conference/Other Audio Visual Means (VC/OAVM). Manish Gupta, Managing Director, chaired the session in the absence of Harsha Raghavan, Non-Executive Director and Chairperson. Ayush Khandelwal & Associates served as the Scrutinizer for the e-voting process.

Voting Participation

The record date for the meeting was September 11, 2026, with a total of 26,852 shareholders on record. While no shareholders attended physically or via proxy, participation through video conferencing was recorded.

Remote e-voting commenced on September 14, 2026, and concluded on September 17, 2026. The total votes polled across all resolutions ranged between 46.2 million and 49.2 million, representing approximately 70% to 75% of outstanding shares.

Key Resolutions Passed

Shareholders transacted both ordinary and special business items. The resolutions included the adoption of financial statements, dividend declaration, director appointments, and auditor ratification.

Prithpal Singh Kochar, who retires by rotation, was eligible and offered himself for reappointment. The resolution received 99.99% support on votes polled. Notably, votes cast by Mr. Rajpal Singh Kochhar, a relative of Mr. Prithpal Singh Kochhar, were declared invalid due to interest in the matter, totaling 3,030,400 shares.

The company also ratified the remuneration payable to Kirit Mehta & CO LLP, Cost Accountants, for the financial year ending March 31, 2027. This resolution saw 99.98% support, with minimal opposition from non-institutional public shareholders.

Governance Updates

A significant governance change occurred with the special resolution to appoint Anil Kumar Matai (DIN: 03122685) as an Independent Director. This appointment strengthens the board’s independent oversight capabilities and was approved with 99.99% of votes in favor.

The detailed voting results and Scrutinizer’s Report have been disseminated to stock exchanges and placed on the company’s website.